Third Party Development Costs definition

Third Party Development Costs mean within Development, the actual invoiced amounts paid by a Party to a CRO, excluding recoverable taxes such as VAT.
Third Party Development Costs means all Third Party costs provided for in any Annual Budget or Initial Budget incurred in connection with the development or construction of the Project on or after the December 16, 2005 but prior to the Project Completion Date.
Third Party Development Costs means costs and expenses for the Development of Licensed Compounds or Products paid or payable by a Party, or for its account, to a Third Party relating to: (i) professional services; (ii) contract research services; (iii) research grants; (iv) clinical grants; (v) consultants; (vi) clinical investigation start-up meetings; (vii) Clinical Trials, including Regulatory Approval Clinical Trials, but excluding Post-Approval Clinical Trials and any Phase 2 Clinical Trial for Davalintide that is on-going as of the Effective Date; (viii) contract labor; (ix) obtaining Regulatory Approval, but excluding costs relating to maintaining Regulatory Approval; and (x) other activities approved by the Parties in the Development Plan.

Examples of Third Party Development Costs in a sentence

  • For clarity, if the Ongoing Studies are Global Studies they are not subject to Section 5.7. ARIAD SWISSCO shall reimburse ARIAD US for ongoing Third Party Development Costs incurred by ARIAD US in the Ongoing Studies, subject to a maximum aggregate amount of US$7,000,000 for the period from the Effective Date until December 31, 2016 and US$7,000,000 for the calendar year 2017 (together, the “Ongoing Studies Budget”).

  • ARIAD SWISSCO shall reimburse the actual, undisputed Third Party Development Costs quarterly within [**] of receipt of ARIAD US’s quarterly invoice and supporting evidence of the Third Party Development Costs having been incurred.

  • ARIAD SWISSCO shall reimburse the actual, undisputed Third Party Development Costs quarterly within [***] of receipt of ARIAD US’s quarterly invoice and supporting evidence of the Third Party Development Costs having been incurred.

  • For clarity, if the Ongoing Studies are Global Studies they are not subject to Section 5.7. ARIAD SWISSCO shall reimburse ARIAD US for ongoing Third Party Development Costs incurred by ARIAD US in the Ongoing [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.

  • Each Party shall bear all Third Party Development Costs that are incurred by or on behalf of such Party or its Affiliates after the Effective Date in connection with the activities in support of such Party’s Independent Studies, subject to Section 5.5(b).

  • As soon as practicable after the completion of each clinical trial within the Independent Studies, the Party conducting such trial shall provide the other Party with the full data set and all results and reports generated in such trial and Controlled by such Party, as well as a statement of the total Third Party Development Costs incurred by such Party in connection with the conduct of such trial.

  • Norgine shall be and remain liable for any Third Party Development Costs Norgine has committed to with respect to any Norgine Independent Studies.

  • Except as otherwise expressly provided, nothing in this Agreement will create or be deemed to create a relationship between the parties to this Agreement, or either of them, and any third person, including a relationship in the nature of a third party beneficiary or fiduciary.


More Definitions of Third Party Development Costs

Third Party Development Costs means costs which are included in the Development Plan budget and which are incurred for services performed by Third Parties.
Third Party Development Costs means the out-of-pocket amounts paid to Third Parties (excluding consultants engaged by a Party on an on-going basis) incurred as an expense in accordance with generally accepted accounting principles and in accordance with the Development Plan (including the budget contained therein) on behalf of a Party, its Affiliates, licensees or sublicensees in carrying out preclinical testing, toxicology testing, human clinical trials, and post-approval marketing studies, but excluding Clinical Manufacturing Costs, Manufacturing Costs and costs associated with seeking, obtaining or maintaining Regulatory Approval in a particular country within the Territory.